News for Delcath Systems, Inc. (DCTH)

Shares of Delcath Systems Inc (DCTH) surged 5.58% in mid-day trading on Apr 14. The stock reached an intraday high of $11.44, before settling at $11.26, up

Delcath Systems (DCTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the

**media[578969]**

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 58.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc

Delcath Systems, Inc. (Nasdaq: DCTH) (the ”œCompany” or ”œDelcath”), an interventional oncology company focused on the treatment of primary and metastati

HEPZATO Revenue (Q4 2024): $13.7 million from 14 active US treatment centers.HEPZATO Revenue (Full Year 2024): $32.3 million.CHEMOSAT Revenue (Q4 2024): $1.4 m

The following slide deck was published by Delcath Systems, Inc.

Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ETCompany ParticipantsDavid Hoffman - General Counsel, Corporate...

Delcath Systems (DCTH) delivered earnings and revenue surprises of 150% and 33.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Delcath Systems, Inc. (Nasdaq: DCTH) (”œDelcath” or the ”œCompany”), an interventional oncology company focused on the treatment of primary and metastati

Transaction Overview On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 9,536,647 shares in Biof

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Delcath Systems Inc. (DCTH) touched a new 52-week high of $16.97 last week, and that reflects a gain of over 100% in less than 6 months..

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a significant move by adding 412,087 shares of OptiNose Inc. (NASDAQ: OPTN) to its portfo

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) significantly increased its investment in InspireMD Inc. by acquiring an additional 7,419,918

The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.